Lv11
56 积分 2024-02-28 加入
Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments
1小时前
已完结
Toxicologic Pathology Forum*: Summary of the 2024 Society of Toxicologic Pathology Town Hall and 2025 STP Member Survey on Determining and Communicating Adversity
6个月前
已完结
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
7个月前
已完结
Toxicological Aspects of PROTACs
8个月前
已完结
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
8个月前
已完结
Targeted protein degradation: from mechanisms to clinic
1年前
已完结
Targeted protein degradation: from mechanisms to clinic
1年前
已完结
皖公网安备34019202002308
